KDIGO to develop new guideline for autosomal dominant polycystic kidney disease
Click Here to Manage Email Alerts
Kidney Disease: Improving Global Outcomes is developing a new guideline for the treatment of patients with autosomal dominant polycystic kidney disease, according to a press release from the organization. The process could take up to 2 years.
Project co-chairs Olivier Devuyst, MD, PhD, of the University of Zurich in Switzerland, and Vicente Torres, MD, PhD, of the Mayo Clinic in the United States, are recruiting their work group and drafting the scope of work. Both chaired a KDIGO Controversies Conference on autosomal dominant polycystic kidney disease (ADPKD) in 2014, the release stated.
“We are very fortunate to have enlisted Olivier and Vicente to lead this effort,” Michel Jadoul, MD, co-chair of KDIGO, said in the release. “Since our Controversies Conference, we have been monitoring the ADPKD research landscape and feel this is the right time to begin a guideline on this important topic.”
According to the release, the guideline will address treatments for the disease that have “emerged in recent years” and will include robust patient representation and input.
"Hearing directly from patients about the difficulties they face made a difference for everyone at the Controversies Conference,” KDIGO co-chair Wolfgang C. Winkelmayer, MD, ScD, Gordon A. Cain chair in nephrology and professor of medicine at Baylor College of Medicine in Houston, said. “It led to a commitment by KDIGO to wait for new evidence and then move ahead to a full guideline with recommendations that can improve outcomes for patients around the world."
Collapse
Read more about
Click Here to Manage Email Alerts